Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis

Conclusions
Currently available IL-21 ELISA kits should not be used to counsel individuals with multiple sclerosis considering treatment with alemtuzumab.

Source: Journal of Neurology, Neurosurgery and Psychiatry - June 10, 2014 Category: Neurosurgery Authors: Azzopardi, L., Thompson, S. A. J., Harding, K. E., Cossburn, M., Robertson, N., Compston, A., Coles, A. J., Jones, J. L. Tags: Immunology (including allergy), Multiple sclerosis Source Type: research